MTOR and breast cancer: In the first place, combination therapy induced 4T1 and MDA-MB-231 breast cancer cell apoptosis via the activation of the JNK signaling pathway, inhibiting the AKT/mTOR signaling pathway and down-regulating the Bcl-2 and IAP family (Figure 7).